Comparative study on the efficacy and safety of zoledronic acid and sodium ibandronate in treating bone metastasis in breast cancer patients

Abstract

Objective To retrospectively evaluate the efficacy and safety of zoledronic acid and sodium ibandronate in treating bone metastasis in breast cancer patients.Methods The study included 47 patients who were treated with zoledronic acid and sodium ibandronate respectively from Aug.2006 to Mar.2011. KaplanMeier curve and Log rank test were adopted to detect the difference in survival time of skeletal related event (SRE) and survival rate between patients treated with different medicine,and x2 test was uscd to rcveal thc rate difference of pain killing effects and adverse effects.Results 1.The total effective rate of pain killing was 88.9％ and 85％ respectively.The difference had no statistical significance(P =0.467).2.The 1,2 and 3-year-survival rate in zoledronic acid group and sodium ibandronate group was 88.7％,44.4％,24.2％ vs 94.7％,40.5％,5.8％.The difference had no statistical significance(P =0.744).3.The 2,3,and 4-year-survival rate in zoledronic acid group and sodium ibandronate group was 70.4％,40.7％,23.1％ vs 85％,46.7％,17.5％.The difference had no statistical significance( P =0.994).4.The 1,2 and 3-year SRE-free overall survival rate of the group with metastasis first to bone only was 92％,50.8％,and 23.8％,while the rate of the group with first metastasis to visceral organs was 85.4％,21.4％,and 5.3％ ( P =0.012).5.The 2 and 3-year overall survival rate of the group with metastasis first to bone only was 95.8％ and 74.2％ respectively,while the rate of the group with first metastasis to visceral organs was 56.5％ and 10.1％ ( P ＜0.001 ).The difference of 4 and 5 had statistical significance.The difference of zoledronic acid group and sodium ibandronate group in rate of adverse effects had no statistical significance.Conclusions Compared to sodium ibandronate,zoledronic acid has no superiority in either delaying the occurrence of SRE or improving overall survival rate.The -2are similar in incidence of adverse effects and pain control.The prognosis of patients whose first presentation is complicated by metastasis to other organs is poor. Key words: Breast cancer; Bone metastasis; Skeletal related event; Zoledronic acid; Sodium ibandronate